GenVec Inc. Receives NIAID Biodefense Program Grant For Development Of Broadly Applicable Vaccine Technology

GenVec, Inc. (Nasdaq:GNVC) announced today that it has received a $430,000 Phase I Small Business Innovation Research award from the National Institute of Allergy and Infectious Diseases Biodefense Program to support the company's efforts to develop novel adenovector-based vaccine technology. The funding will support research to advance GenVec's adenovector technology to develop a range of vaccines based on novel serotypes of adenovirus. The new vectors produced under this grant will incorporate influenza genes to assess their improved immunogenicity.